# Pmv Pharmaceuticals (PMVP) — Earnings

PMVP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pmvp/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.41 |
| EPS estimate | −$0.38 |
| EPS surprise | −6.97% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 7, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1699382/000095017025104588/pmvp-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 7, 2025 | −$0.38 | −$0.41 | -6.97% | — | — |
| Q1 2025 | May 9, 2025 | −$0.37 | −$0.34 | 8.72% | — | — |
| Q4 2024 | Mar 3, 2025 | −$0.39 | −$0.45 | -15.98% | — | — |
| Q3 2024 | Nov 7, 2024 | −$0.35 | −$0.37 | -7.03% | — | — |
| Q2 2024 | Aug 8, 2024 | −$0.35 | −$0.02 | 94.29% | — | — |
| Q1 2024 | May 9, 2024 | −$0.36 | −$0.30 | 16.67% | — | — |
| Q4 2023 | Feb 29, 2024 | −$0.37 | −$0.30 | 18.92% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.46 | −$0.34 | 26.55% | — | — |
| Q2 2023 | Aug 9, 2023 | −$0.49 | −$0.38 | 21.76% | — | — |
| Q1 2023 | May 10, 2023 | −$0.46 | −$0.42 | 8.12% | — | — |
| Q4 2022 | Mar 1, 2023 | −$0.43 | −$0.42 | 2.64% | — | — |
| Q3 2022 | Nov 8, 2022 | −$0.42 | −$0.40 | 3.78% | — | — |
| Q2 2022 | Aug 9, 2022 | −$0.40 | −$0.38 | 5.33% | — | — |
| Q1 2022 | May 10, 2022 | −$0.39 | −$0.41 | -4.75% | — | — |
| Q4 2021 | Mar 1, 2022 | −$0.34 | −$0.40 | -19.15% | — | — |
| Q3 2021 | Nov 12, 2021 | −$0.30 | −$0.33 | -11.22% | — | — |
| Q2 2021 | Aug 13, 2021 | −$0.28 | −$0.29 | -3.57% | — | — |
| Q1 2021 | May 14, 2021 | −$0.26 | −$0.26 | 0.00% | — | — |
| Q4 2020 | Mar 3, 2021 | −$0.51 | −$0.23 | 54.90% | — | — |

## Frequently Asked Questions

### When did Pmv Pharmaceuticals (PMVP) last report earnings?

Pmv Pharmaceuticals last reported on Aug 7, 2025, covering fiscal Q2 2025.

### Did PMVP beat earnings estimates?

No. Pmv Pharmaceuticals reported EPS of −$0.41 for Q2 2025 against a −$0.38 estimate — a 6.97% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).